Transformative bispecific antibody technology

F-star is developing a promising pipeline of immuno-oncology therapies with its innovative bispecific antibody technology, which is ideally suited to uncover novel combinatorial biology. To download the full article, please sign in.

Page of
Go to the profile of F-star


F-star Biotechnology Ltd is an immuno-oncology focused biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve the standard of care for patients.

Comments are disabled